Taltz ® (ixekizumab) injection

80 mg/mL

This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.

How long after stopping Taltz® (ixekizumab) before psoriasis relapses?

For Taltz (ixekizumab) responders at week 12 who were rerandomized to treatment withdrawal (ie, placebo), the median time to relapse was 164 days.

US_cFAQ_IXE315_SYMPTOM_RETURN_AFTER_STOP_TREATMENT_PsO
US_cFAQ_IXE315_SYMPTOM_RETURN_AFTER_STOP_TREATMENT_PsO
en-US

Relapse of Psoriasis Following Ixekizumab Treatment Discontinuation

For the analyses summarized below, response was defined as a static Physician Global Assessment (sPGA) score of 0 (clear skin) or 1 (minimal) and relapse was defined as a sPGA score of ≥3.1

In 2 phase 3 clinical trials, patients who were originally randomized to ixekizumab and who responded to treatment at week 12 were rerandomized to an additional 48 weeks of ixekizumab 80 mg every 4 weeks or placebo.1

In those week 12 responders to ixekizumab who were rerandomized to treatment withdrawal (ie, placebo), 7% maintained their clinical response at week 60. The median time to relapse was 164 days.1

In responders who were rerandomized to treatment with ixekizumab every 4 weeks, 75% maintained their response at week 60.1

Reference

1Taltz [package insert]. Indianapolis, IN: Eli Lilly and Company; 2021.

Date of Last Review: July 26, 2021


Contact Lilly

Call Us

If you need information about a Lilly product or want to report an Adverse Event or Product Complaint, you may call us.

Available Mon - Fri, 9am - 7pm EST

Or you can

Chat with us

Chat with us

Submit a Request

Visit Us @LillyMedical